BGI-HL OHA Lab inaugurated in Harbin, initiating colorectal cancer risk assessment for 800,000
On May 10, 2024, the BGI-Heilongjiang Omics Health Axis Intelligent Laboratory (BGI-HL OHA Intelligent Laboratory) was inaugurated in Harbin, Heilongjiang province, China, marking a significant advance in the province’s efforts to address public health challenges. Utilizing the ‘13311i GigaLab’ technological framework, this facility supports vital life…
NUH LAUNCHES NEW DIGESTIVE CENTRE TO PUSH NEW FRONTIERS IN EARLY CANCER DETECTION AND CARE EXCELLENCE
The National University Hospital (NUH) is embarking on a major initiative to establish the National University Centre for Digestive Health, slated for completion in the first half of 2025. With a vision to be the region’s leading academic centre for…
Transcenta Announces Collaboration with Agilent to Develop a Claudin18.2 Companion Diagnostic to Support Osemitamab (TST001) Global Phase III Trial
Transcenta Holding Limited (“Transcenta”) (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, and Agilent Technologies, announce a collaboration to develop a Claudin18.2 (CLDN18.2) companion diagnostic to support TranStar301 global…
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen
Marengo Therapeutics, Inc, a clinical-stage biotech company pioneering a new way to activate T cells that target the Vβ chain of the T cell receptor (TCR) and select the right T cell subsets against cancer, today announced that Ipsen (Euronext:…
Sequel’s twiist™ Automated Insulin Delivery System Receives FDA 510(k) Clearance
Sequel Med Tech, LLC, a company developing state-of-the-art insulin delivery technologies, today announced its partner, DEKA Research & Development Corp., has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the innovative twiist™ Automated Insulin Delivery (AID)…
Groundbreaking New Blood Test Offers Early Pancreatic Cancer Diagnosis Study Says
As reported in today’s issue of the journal Metabolites, researchers at Metabolomycs, a California-based biotechnology company, for the first time applied targeted mass spectrometry to show that pancreatic cancer arises through changes in cellular metabolism and that these changes can be measured with…
Innovent Announces First Participant Dosed in a Phase I Study of IBI3002 (an anti-IL-4Rα/TSLP bispecific antibody) in Australia
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announces that the first participant has been dosed in Australia in a first-in-human (FIH) phase…
China Medical University Hospital (CMUH) in Taiwan Upgrades Smart Healthcare with Gen AI
China Medical University Hospital (CMUH) in Taiwan announced its collaboration with Google Cloud in mid-December 2023. Using Google Cloud’s generative AI technology, including MedLM, which is a large language model built on Med-PaLM 2, CMUH has developed a comprehensive “AI-assisted Physician” system which aims to assist…
Andelyn Biosciences and Armatus Bio Partner to Manufacture Suspension-Based AAV Gene Therapy for Rare Neurological Disease Charcot-Marie-Tooth Type 1A (CMT1A)
Andelyn Biosciences, Inc., a pioneering and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Armatus Bio to accelerate manufacturing of their gene therapy treatment for Charcot-Marie-Tooth Type 1A (CMT1A), a rare genetic neurological disease associated with…
Kexing Biopharm Introduces Eribulin Mesylate Injection, Expanding Its Overseas Product Portfolio
On the morning of January 3, Kexing Biopharm signed an international commercialization cooperation agreement on Eribulin Mesylate Injection, securing exclusive commercialization licensing and supply of the product from Xiling Lab Co., Ltd. in 36 countries. This is the fifth major breast cancer…
